Translating our pioneering research to treatments for patients requires cooperative partnerships across many different organizations ranging from universities, hospitals, research centers, biobanks as well as industry partners such as pharmaceutical and biotechnology companies. Without industry partnership, new medicines, treatments and diagnostics for patients stemming from Genuity Science’s research, would not be possible.
Bringing commercial expertise of pharmaceutical and biotechnology companies to Genuity Science’s research will maximize patient benefit of Genuity Science’s research. Working closely with us, our industry partners will have restricted read only access to select de-identified datasets (which contain only the information they need for their specific and approved research study) in order to turn research findings into treatments and diagnostics. Before commencing commercially-partnered research, Genuity Science enters into legal agreements with all partners, which strictly controls their activities. These researchers are prohibited from attempting to identify an individual participant from the data in the database. Read more information on our data stewardship practices.
Genuity Science began a project with Alumis Inc in 2024. The goal of this project is to bring together a comprehensive database to enable a better understanding of the drivers of immune dysfunction, with the aim of optimising therapeutic outcomes for patients with immune-related diseases.
Genuity Science began a multi-year agreement in 2024 with Ionis Pharmaceuticals. The goal of the collaboration is to bring together a comprehensive database to enable better understanding of disease mechanisms which when combined with Ionis’ proprietary antisense technology has the potential to significantly expedite the drug development process through more direct translation of targets into therapies.
Genuity Science began a multi-year agreement with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The aim is to understand patient variability among lupus and lupus nephritis patients to better understand disease severity and symptoms and facilitate the targeting of more refined patient subpopulations that may enable the advancement of therapeutic agents.
Genuity Science began a multi-year agreement in 2021 with GSK. The goal of the engagement is to bring together a comprehensive database to enable the evaluation of variability among patients with heart failure and among patients with liver disease in order to better understand disease severity and symptoms. It is designed to facilitate the identification of more refined patient subpopulations that may eventually enable the advancement of specific therapeutic agents in specific patient subpopulations.
Genuity Science began a multi-year agreement in 2022 with Vesalius Therapeutics. The goal of the collaboration is to bring together a comprehensive database to enable the evaluation of variability among patients with Parkinson’s disease to better understand disease severity and symptoms. It is designed to facilitate the identification of more refined patient subpopulations that may eventually enable the advancement of specific therapeutic agents in specific patient subpopulations.
